Trials / Completed
CompletedNCT00133627
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines. These medicines block the release of histamine, a substance in the body that is released when an allergic reaction occurs. Novartis (NVS) has developed an eye drop formulation of a well tried antihistamine called ketotifen. This study will compare the efficacy and the tolerability of ketotifen eye drops with emedastine, which is a popular treatment for seasonal allergic conjunctivitis in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketotifen |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-08-23
- Last updated
- 2011-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00133627. Inclusion in this directory is not an endorsement.